[Isradipine-SRO: antihypertensive efficacy, central and peripheral hemodynamic effects in patients with hypertensive disease].
OBJECTIVE
To assess antihypertensive efficacy of isradipine, to study its effects on central and peripheral hemodynamics, and to investigate relationships between state of microcirculation and response to treatment.


METHODS
Isradipine was given for 12 weeks to 30 patients (16 men, 14 women, mean age 50.2+/-9.8 years) with I-II stage mild and moderate hypertension. Twenty four hour blood pressure monitoring, assessment of parameters of central hemodynamics and state of microcirculation were carried out before and after 12 weeks of isradipine administration.


RESULTS
Administration of isradipine was associated with improved sense of well-being and significant lowering of 24-hour, diurnal and nocturnal systolic/diastolic blood pressure (by 6.4/12.7, 7.6/9.4, 10.5/13.4%, respectively). Average 24-hour heart rate increased mainly during daytime (by 10.6%). Mean hemodynamic blood pressure was lowered by 16.3% due to reduction of total peripheral vascular resistance. There occurred redistribution of types of microcirculation with increase of proportion of normocirculatory and decrease - of spastic types. Changes of parameters of microcirculation at rest and during functional tests evidenced for resolution of baseline arteriolar spasm, stasis and venous congestion in microcirculatory vascular bed. Patients who responded to isradipine more often had spastic (50%) and congestive (35%) types of microcirculation. Patients with hyperemic type did not respond to isradipine. Most frequent side effect was flushing (23.3%) because of which 2 patients stopped taking the drug.
Podzolkov
V I
VI
Bartieva
D M
DM
Makolkin
V I
VI
D000328:Adult; D000368:Aged; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D017275:Isradipine / Q000494:pharmacology* / Q000627:therapeutic use*; D008297:Male; D008833:Microcirculation / Q000187:drug effects* / Q000503:physiopathology; D008875:Middle Aged; D016896:Treatment Outcome
D002121:Calcium Channel Blockers; D017275:Isradipine